Welcome to our dedicated page for Cormedix SEC filings (Ticker: CRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CorMedix Inc. (CRMD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a detailed view of its financial condition, governance, and material events. CorMedix is a Nasdaq Global Market–listed biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases, including DefenCath for catheter-related bloodstream infection prevention and a portfolio of anti-infective and hospital products acquired through Melinta Therapeutics LLC.
Current reports on Form 8-K document significant developments such as the completion of the Melinta acquisition, the related contingent payment and registration rights agreements, the issuance of convertible senior notes, equity offerings, and preliminary or final quarterly results. For example, a Form 8-K filed on November 12, 2025 furnishes third-quarter 2025 financial results and guidance updates, while earlier 8-Ks describe the Melinta transaction terms and the convertible notes offering used in part to fund the deal.
Proxy statements on Schedule 14A provide insight into CorMedix’s corporate governance and capital structure decisions. A definitive proxy statement filed in October 2025 outlines proposals for a special meeting, including amendments to the company’s stock incentive plan, ratification of certificate of designation amendments, and changes to its certificate of incorporation affecting preferred stock voting rights.
Investors can also use this page to access periodic reports referenced in the company’s proxy and 8-K filings, which contain audited financial statements, risk factors, and management’s discussion and analysis. These filings explain how CorMedix reports revenue from DefenCath and the Melinta portfolio, records goodwill and intangible assets, and accounts for items such as deferred tax assets and non-GAAP measures like adjusted EBITDA.
In addition, insider and capital markets–related filings are available, including disclosures about equity offerings, convertible notes, and voting results from annual and special meetings. Stock Titan’s interface pairs these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, 8-K, and proxy materials, helping users quickly understand transaction terms, clinical program disclosures, and changes in guidance without reading every page.
CorMedix Inc. completed its previously announced private placement of $150,000,000 aggregate principal amount of convertible senior notes due 2030, issued in reliance on Section 4(a)(2) of the Securities Act. The company entered into an indenture with U.S. Bank Trust Company, National Association, as trustee, and the indenture and form of note are filed as Exhibits 4.1 and 4.2.
The notes bear a stated rate reflected in the form of the notes as 4.00% and have an initial conversion rate of 74.2515 shares per $1,000 principal amount (approximately $13.47 per share implied by that rate). The notes and any common stock issuable upon conversion have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption.
On 8 Aug 2025, individual investor Shaibatalhamd Aymen Abdalkader filed Amendment No. 2 to Schedule 13G, revealing a passive ownership position in CorMedix Inc. (CRMD).
- Shares owned: 4,645,630 common shares.
- Ownership percentage: 6.22 % of CorMedix’s outstanding stock, exceeding the 5 % disclosure threshold.
- Control rights: Sole voting and sole dispositive power over all reported shares; no shared control.
- Intent: Filer certifies the stake is not intended to influence or change control of the issuer.
No purchase prices, transaction dates, or financing details were disclosed. While the filing signals meaningful individual interest in CRMD, it conveys a passive stance and does not, by itself, indicate imminent strategic or governance changes.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.
CorMedix Inc. (Nasdaq: CRMD) has launched a follow-on equity offering under its shelf registration statement, filing a Rule 424(b)(5) prospectus supplement dated June 26 2025. The company is issuing 6,604,507 shares of common stock, with sole book-runner RBC Capital Markets purchasing the shares at $12.641 per share. This represents a 15.6% discount to the June 25 2025 closing price of $14.97. Gross proceeds to CorMedix are expected to be approximately $83.5 million before offering expenses.
The underwriters have a 30-day option to buy up to an additional 990,676 shares, which, if fully exercised, would increase the total raise to roughly $96 million. Shares are expected to be delivered on or about June 30 2025.
The prospectus highlights numerous risk factors, including: sustained operating losses, reliance on a single commercial product (DefenCath), dependence on third-party reimbursement, significant customer concentration, and the need for future financings that could be dilutive or on unfavorable terms. The document expressly cautions that forward-looking statements are subject to uncertainty and that past information may not reflect current conditions.
Key transactional terms
- Offering size: 6.60 million shares
- Offer price to underwriters: $12.641 per share
- Gross proceeds: ~$83.5 million (excluding option)
- Over-allotment option: 990,676 shares (30 days)
- Expected closing: June 30 2025
No specific use-of-proceeds breakdown is provided in the excerpt; investors are directed to the “Use of Proceeds” section (page S-6) for details. The filing reiterates that neither the SEC nor state regulators have approved or disapproved the securities and that investing involves substantial risk.
CorMedix Inc. (Nasdaq: CRMD) has filed a preliminary prospectus supplement under Rule 424(b)(5) for a common-stock offering of up to US$85 million. The company has not yet disclosed the number of shares or the final offering price, but the last reported market price on 25 June 2025 was $14.97 per share. RBC Capital Markets is the sole book-running manager, and the underwriters hold a 30-day option to purchase additional shares. The shares will be offered on Nasdaq or through negotiated transactions at prevailing or negotiated prices.
The filing forms part of CorMedix’s shelf registration statement dated 22 May 2024. Key sections include Use of Proceeds (S-6), Dilution (S-7) and Underwriting (S-10). Although precise use of proceeds is not specified in this preliminary document, management cites a continued need to finance operations and commercial expansion.
Risk highlights listed on pages S-4 onward emphasise: (i) a history of operating losses and the possibility of never achieving sustained profitability; (ii) heavy reliance on a single approved product, DefenCath®, with concentrated customers and reimbursement uncertainties; (iii) potential dilution and unfavourable terms from future financings; and (iv) regulatory and commercialisation uncertainties for pipeline products.
Investors are advised to review the full prospectus supplement, incorporated documents and forward-looking statements for detailed risk disclosures before committing capital.
CorMedix (NASDAQ:CRMD) held its 2025 Annual Meeting of Stockholders on June 24, 2025. Shareholders voted on three key proposals: election of seven directors, advisory vote on executive compensation, and ratification of the independent auditor.
All seven director nominees were successfully elected with Joseph Todisco receiving the highest approval (18.3M votes). The non-binding advisory vote on executive compensation passed with 16.1M votes in favor. Shareholders also approved CBIZ CPAs P.C. as the independent auditor with 45.5M votes in favor.
On 23 June 2025, CorMedix Inc. (CRMD) filed a Form 8-K under Item 7.01 (Regulation FD). The company disclosed that it had released a press release (attached as Exhibit 99.1) providing an update on its Large Dialysis Organization (LDO) customer and confirmed that implementation is planned for the second half of 2025. No financial metrics, contractual terms, or quantitative guidance were included in the filing. Because the information is being furnished, not filed, it is exempt from Section 18 liability and will not be automatically incorporated into other SEC filings unless specifically referenced.
FAQ
What is the current stock price of Cormedix (CRMD)?
What is the market cap of Cormedix (CRMD)?
